



UNIVERSITÄT  
LEIPZIG



# **PEVO basket trial, combining immunotherapy with an epidrug in squamous cell carcinomas**

February 13th 2023, Bled

Gábor Balogh

# Introduction

PEVO: Pembrolizumab Vorinostat:

- Combination Therapie:
  - ▶ combining multiple drugs in one therapy approach
- Basket trial:
  - ▶ including multiple cancer “types” in one study approach (i.e. different sites of origins)
- Individualised/personalised medicine:
  - ▶ designing an individual, patient suited therapy approach on the basis of known biomarkers

# Introduction

Combining immunotherapy with an epidrug: -> increasing the ORR (overall response rate)

– Pembrolizumab:

- ▶ immunodrug, Checkpoint inhibitor
- ▶ humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, and cervical cancer.
- ▶ targets the programmed cell death protein/ligand interaction (PD-1/PD-L1) between lymphocytes and cells (binds and blocks PD-1 located on lymphocytes)

# Introduction

- Vorinostat:
  - ▶ epidrug
  - ▶ Histone deacetylase inhibitors (HDI)
  - ▶ Vorinostat's inhibition of histone deacetylases results in the accumulation of acetylated histones and proteins, including transcription factors crucial for the expression of genes

# PEVO trial study design

Patientinclusion:

## PEVO<sup>SQ</sup> inclusions

✓ Inclusions **completed** Early May 2022



## **further reading:**

E de Guillebon et al.:

Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial biomarkers following the pembrolizumab and vorinostat treatment


PMID: 33865192 PMCID: PMC8066350 DOI: 10.1016/j.esmoop.2021.100106

# Snakemake:

DAG:



# Pipelines:



## **preliminary results:**

- WES-SNP**
  - ▶ somatic:
    - ▶ lofreq\_somatic
    - ▶ neusomatic
    - ▶ mutect\_2
    - ▶ dragen\_somatic

## **preliminary results:**

- WES-SNP**

- ▶ somatic:**


- ▶ lofreq\_somatic
    - ▶ neusomatic
    - ▶ mutect\_2
    - ▶ dragen\_somatic

- ▶ germline:**


- ▶ deepvariant
    - ▶ bcf\_tools
    - ▶ lofreq
    - ▶ dragen\_germline

# somatic SNPs:

Venn Diagram for snps:  
mutect2\_somatic\_filtered, lofreq\_somatic, dragenNEW\_somatic, neusomatic\_passed\_filtered




# somatic SNPs:




# germline SNP:

Venn Diagram for snps:  
lofreq, dragenNEW\_germline, bcf\_bed, deepvariant\_passed\_filtered



# germline SNP:



## Fusion tools:


- StarFusion
- FusionCatcher
- Arriba
- Dragen

## Fusion tools:


- StarFusion
- FusionCatcher
- Arriba
- Dragen
- all of them are validated with FusionInspector
- semiautomated BLAT verification

# preliminary results:

Venn Diagram for Fusions:  
STARfusion, FusionCatcher, BLAT, ARRIBA, DRAGEN



# preliminary results:





UNIVERSITÄT  
LEIPZIG



# Thank You!

**Gábor Balogh**

IZBI Leipzig

Department for Computer Science

[gabor@bioinf.uni-leipzig.de](mailto:gabor@bioinf.uni-leipzig.de)


<https://www.bioinf.uni-leipzig.de>



# our preliminary results:

TIS-DNA – TIS-RNA sample pairing:

relative shared variants between DNA and RNA





# our preliminary results:

relative shared variants between BLD and TIS

